Copyright: ©Author(s) 2026.
World J Gastroenterol. Jan 21, 2027; 33(3): 123331
Published online Jan 21, 2027. doi: 10.3748/wjg.123331
Published online Jan 21, 2027. doi: 10.3748/wjg.123331
Table 1 Baseline characteristics, n (%)
| Characteristics | Cohort 1 (n = 112) | Cohort 2 (n = 42) |
| Age, median (range), years | 67 (44-88) | 63 (48-82) |
| Sex | ||
| Male | 82 (73.2) | 34 (81.0) |
| Female | 30 (26.8) | 8 (19.0) |
| ECOG PS | ||
| 0 | 18 (16.1) | 3 (7.1) |
| 1 | 83 (74.1) | 30 (71.4) |
| 2 | 4 (3.6) | 1 (2.4) |
| Not known | 7 (6.3) | 8 (19.0) |
| AJCC stage1 | ||
| I | 7 (6.3) | - |
| II | 9 (8.0) | - |
| III | 58 (51.8) | - |
| IVA | 37 (33.0) | - |
| IVB | 0 | 42 (100.0) |
| Lines of treatment | ||
| 1 L | 74 (66.1) | 16 (38.1) |
| ≥ 2 L | 23 (20.5) | 26 (61.9) |
| Unknown | 15 (13.4) | 0 |
Table 2 Outcomes between patients with locally advanced (cohort 1) and advanced (cohort 2) esophageal squamous cell carcinoma, n (%)
| Characteristics | Cohort 1 (n = 112) | Cohort 2 (n = 42) |
| CR | 6 (5.4) | 2 (4.8) |
| PR | 44 (39.3) | 18 (42.9) |
| SD | 34 (30.4) | 11 (26.2) |
| PD | 3 (2.7) | 5 (11.9) |
| Non-CR/Non-PD | 25 (22.3) | 6 (14.3) |
| ORR, % (95%CI) | 44.6 (35.2-54.3) | 47.6 (32.0-63.6) |
| DCR, % (95%CI) | 97.3 (92.4-99.4) | 88.1 (74.4-96.0) |
| OS, median (months) (95%CI) | 34.5 (26.2-NE) | 22.7 (14.9-61.8) |
| PFS, median (months) (95%CI) | 16.7 (11.5-25.7) | 8.5 (4.7-14.9) |
Table 3 Treatment-emergent adverse events occurred in more than 5% of patients with locally advanced (cohort 1) or advanced (cohort 2) esophageal squamous cell carcinoma, n (%)
| TEAEs | Cohort 1 (n = 112) | Cohort 2 (n = 42) | ||
| Any grade | Grade ≥ 3 | Any grade | Grade ≥ 3 | |
| Any TEAEs | 72 (64.3) | 17 (15.2) | 31 (73.8) | 7 (16.7) |
| Anemia | 30 (26.8) | 0 | 11 (26.2) | 0 |
| White blood cell decreased | 24 (21.4) | 1 (0.9) | 14 (33.3) | 0 |
| Lymphocyte count decreased | 19 (17.0) | 8 (7.1) | 8 (19.0) | 2 (4.8) |
| Hypoalbuminemia | 19 (17.0) | 0 | 5 (11.9) | 0 |
| Neutrophil count decreased | 17 (15.2) | 6 (5.4) | 11 (26.2) | 5 (11.9) |
| Platelet count decreased | 11 (9.8) | 1 (0.9) | 3 (7.1) | 0 |
| Oropharyngeal pain | 11 (9.8) | 1 (0.9) | 1 (2.4) | 0 |
| Hypokalemia | 9 (8.0) | 0 | 2 (4.8) | 1 (2.4) |
| Cough | 8 (7.1) | 0 | 2 (4.8) | 0 |
| Hyponatremia | 7 (6.3) | 1 (0.9) | 4 (9.5) | 0 |
| Nausea | 7 (6.3) | 1 (0.9) | 4 (9.5) | 0 |
| Alanine aminotransferase increased | 6 (5.4) | 0 | 4 (9.5) | 0 |
| Radiation esophagitis | 6 (5.4) | 0 | 3 (7.1) | 0 |
| Gastrointestinal disorders | 6 (5.4) | 0 | 1 (2.4) | 0 |
| Hypothyroidism | 6 (5.4) | 0 | 0 | 0 |
| Body pain | 6 (5.4) | 0 | 0 | 0 |
- Citation: Feng GJ, Fu CR, Wang F, Li JC, Jiang Y, Wang XY, Yang BH, Xu WC, Zhang YW, Cheng XY, Ge XL, Xia XJ, Xi HM, Zhao XS, Ma HB, Zhao XX, Wang X, Li BS. Anlotinib plus radiotherapy or chemoradiotherapy in locally advanced or advanced esophageal squamous cell carcinoma: A multicohort, real-world study. World J Gastroenterol 2027; 33(3): 123331
- URL: https://www.wjgnet.com/1007-9327/full/v33/i3/123331.htm
- DOI: https://dx.doi.org/10.3748/wjg.123331